Central nervous system immature teratoma

Summary

Central nervous system immature teratoma (MONDO:0003735) is a disease and 1 clinical trial. Top therapeutic interventions include ifosfamide. A subtype of central nervous system teratoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	central nervous system immature teratoma
Mondo ID	MONDO:0003735
DOID	DOID:6019
NCIT	C7014
UMLS	C1332883
MedGen	272442
GARD	0023640
Is cancer (heuristic)	no

Also known as: central nervous system immature teratoma · CNS immature teratoma · immature teratoma · immature teratoma of central nervous system · immature teratoma of CNS · immature teratoma of the central nervous system · immature teratoma of the CNS

Disease family

This is a subtype of central nervous system teratoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › nongerminomatous germ cell tumor › teratoma › central nervous system teratoma › central nervous system immature teratoma

Related subtypes (5): spinal cord intramedullary teratoma, adult central nervous system teratoma, central nervous system mature teratoma, pineal region teratoma, spinal cord dermoid cyst

Subtypes (3): adult central nervous system immature teratoma, childhood central nervous system immature teratoma, pineal region immature teratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04684368	PHASE2	RECRUITING	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IFOSFAMIDE	4	1